In receptor assays, pramlintide had lower potency for human amylin receptor activation than the mutated rat amylin analogs.
In plain wordsIn lab tests, pramlintide activated human amylin receptors less potently than the modified rat amylin peptides.
- Peptide
- Pramlintide (Symlin)
- Outcome
- DecreaseAmylin receptor activation potency
- Study
n: not reported in source
human amylin and calcitonin receptor activation assays- Comparator
- mutated rat amylin analogs
- Outcome group
- Receptor activity and mechanism · Pharmacology
- Studied dose
- Dose not stated
Source sentences
These mutated peptide activators also showed higher potency for human amylin and calcitonin receptor activation than a clinically available amylin receptor activator pramlintide.
1 context sentence(design, population, supporting numbers)
Using these affinity-enhancing mutations, three representative rat amylin analogs with thirty-seven amino acids were made to test the potency increase for amylin and calcitonin receptor activation.